Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing–Based Cervical Screen-and-Treat Program in El Salvador

Karla Alfaro, MD, MPH1; Mauricio Maza, MD, MPH1; Juan C. Felix, MD2; Julia C. Gage, PhD, MPH3; Philip E. Castle, PhD, MPH4; Todd A. Alonzo, PhD5; Andrea Chacón, MD6; Enrique González, MD6; Montserrat Soler, PhD, MPH7; Gabriel Conzuño-Rodriguez, MD, MPH1; Rachel Masch, MD, MPH1; and Miriam Cremer, MD, MPH1,7

PURPOSE The Cervical Cancer Prevention in El Salvador (CAPE) project is a public-sector intervention introducing lower-cost human papillomavirus (HPV) testing in all four departments of the Paracentral region that screened a total of 28,015 women. After demonstrating success of an HPV screen-and-treat (S&T) algorithm over colposcopy management in the first two phases, the third phase scaled up the S&T strategy. We present results from phase III and evaluate S&T components across the entire project.

METHODS During phase III, 17,965 women age 30-59 years underwent HPV testing. HPV-positive women were asked to return and, if eligible, received gas-based cryotherapy. We compare loss to follow-up and time intervals between S&T steps across the three phases.

RESULTS There were no differences in HPV positivity across phases (phase I, 11.9%; phase II, 11.4%; phase III, 12.3%; P = .173). Although most HPV-positive women completed indicated follow-up procedures within 6 months in phases I (93.3%, 111 of 119) and II (92.3%, 429 of 465), this proportion declined to 74.9% (1,659 of 2,214; P < .001) in phase III. Mean days between testing and delivery of results to patients increased over program phases (phase I, 23.2 days; phase II, 46.7 days; phase III, 99.8 days; P < .001).

CONCLUSION A public-sector implementation of an HPV-based S&T algorithm was successfully scaled up in El Salvador, albeit with losses in efficiency. After CAPE, the Ministry of Health changed its screening guidelines and procured additional tests to expand the program.

INTRODUCTION Although cytology-based cervical cancer screening continues to be widely used, molecular testing of the human papillomavirus (HPV) has emerged as a more sensitive screening tool. In developing countries, low quality of cytology services, lack of adequately trained health providers, and high rates of loss to follow-up have further limited the success of cytology-based screening. Recognizing these constraints and the advantages of molecular HPV testing, the WHO has created guidelines for the use of HPV screening tests for cervical cancer in low-resource settings. In these guidelines, women who screen HPV positive can bypass colposcopic examination and undergo a visual assessment to determine eligibility for immediate treatment with cryotherapy. The feasibility of such screen-and-treat (S&T) paradigms has been assessed using different combinations of HPV screening and ablative treatment modalities.

Despite the potential of HPV testing, the high cost of these assays has hampered widespread adoption of S&T. Currently, one low-cost HPV test (careHPV, QIAGEN, Gaithersburg, MD) is prequalified by the WHO, but there are other tests in development. There is a need for evidence of best practices in HPV testing implementation in lower-resource settings. Public-sector HPV screening projects have been successful but have used cytology as a triage test or colposcopy with biopsy to confirm diagnosis before treatment. The feasibility of the HPV test as a screening tool has not been confirmed in regions with limited capacity for cytology and histology.

Here we evaluate outcomes on the basis of the first public-sector S&T intervention using lower-cost HPV testing. The project took place in El Salvador, where cervical cancer mortality is 18.5 per 100,000 women (age adjusted), and the estimated screening rate is one of the lowest in Latin America at 19%. HPV vaccination is not yet available in the public sector. Previous research has shown that adherence to a cytology-based regimen is poor at 44%. To address this issue, in 2012 the El Salvador Ministry of Health (MOH) submitted a proposal to obtain careHPV tests.
through the QiagenCares donation program. The nonprofit Basic Health International (BHI) served as technical advisor. The application was successful, and the MOH moved forward with the Cervical Cancer Prevention in El Salvador (CAPE) project.

CAPE was designed as a three-phase demonstration project to compare the feasibility of the national colposcopy management strategy against a primary HPV-based S&T paradigm and to incrementally scale up the most successful strategy. The implementation relied on the existing resources of the national public health system, with BHI providing technical support and training to MOH personnel. In CAPE phases I and II,\textsuperscript{19,20} HPV-positive women assigned to the S&T cohort were more likely to complete treatment within 6 months compared with those assigned to the colposcopy management group (phase I: 98.3% v 68.8%, \(P < .001\); phase II: 90.8% v 65%, \(P < .001\)).\textsuperscript{19,20}

In the S&T algorithm, women were screened with the careHPV test. Returning HPV-positive women underwent visual assessment for treatment (VAT) and, if eligible, cryotherapy treatment on the same day. Women were considered ineligible for cryotherapy if the lesion was >75% of the cervix, penetrated the endocervical canal, or was suspicious for cancer, or if VAT was unsatisfactory (the transformation zone was not fully visible). Ineligible women were referred to colposcopy, biopsy, and treatment pending pathology findings. Cost-effectiveness analyses used CAPE and epidemiologic data from El Salvador to model long-term health and economic outcomes of S&T and conventional colposcopy management. S&T resulted in a greater reduction of lifetime cervical cancer risk (a difference of >15%) at a lower cost per woman.\textsuperscript{21,22}

In light of this evidence, the MOH made the decision to expand the S&T protocol as the approach with most potential for a national scale-up. Here we present results from CAPE phase III, compare findings from the S&T cohorts across the three phases, and discuss challenges and lessons learned throughout the project.

METHODS

CAPE was implemented primarily in rural areas of the Paracentral region of El Salvador (Fig 1). Because 80% of the country’s population is covered by the public sector,\textsuperscript{23} CAPE was intended to serve the majority of women in target areas. Phase I was carried out from October 2012 to March 2013, and phase II took place between October 2013 and July 2014 (both in the San Vicente and Cuscatlán departments).\textsuperscript{19,20} In phase I, 2,000 women age 30-49 years were enrolled and divided equally into the S&T and colposcopy management cohorts. In phase II, 8,050 women age 30-49 years were enrolled, with 4,087 assigned to S&T and 3,963 assigned to colposcopy management. Because CAPE was designed as a demonstration project rather than a clinical trial, these were nonrandom assignments made by the MOH using the national census to obtain the number of age-eligible women living in the catchment areas of target health units. Units were then assigned to the two cohorts to match the number of women.

CAPE phase III (May 2015 to April 2017) enrolled 20,000 women aged 30-59 years living in communities served by 63 health units that were screening locations across all four departments of the Paracentral region (San Vicente, Cuscatlán, La Paz, and Cabañas). HPV-positive women were managed only by S&T. Fourteen clinics were equipped with cryotherapy units to provide treatment of eligible HPV-positive women. These were strategically distributed to minimize transportation barriers. Five regional hospitals with colposcopy facilities were designated as referral locations (Fig 1) for HPV-positive women ineligible for cryotherapy. The MOH increased the age range from 30-49 to 30-59 years to reach more at-risk women. According to local census records, this increased the pool...
of potential participants from 98,032 to 132,173. A flow chart of the project’s third phase is presented in Figure 2. Throughout CAPE, training was provided to a total of eight laboratory technicians, 610 community health promoters (CHPs), 360 nurses, and 223 physicians. Before the beginning of phase III, BHI hired and trained five physicians to deliver group trainings to participating MOH doctors, nurses, laboratory technicians, and CHPs. In groups of 30, CHPs attended 2-day workshops that covered the female reproductive system, HPV and cervical cancer risk, and guidance on participant recruitment. Doctors and nurses were also divided into groups of 30 to take part in 1-day training workshops that included the natural history of cervical cancer, HPV testing, treatment options, and
program logistics (eg, preparing HPV samples for transportation, delivering test results, and recording patient data).

Fourteen general practitioners were designated by the MOH to perform VAT and gas-based cryotherapy at the designated triage centers. Training included a 1-day theoretical component and a 4-day practicum with patients. To do this, three provisional clinics were set up in a local health unit. Trainees were supervised by two gynecologists. CHPs scheduled 100 women per day age 30-49 years who were either unscreened or due for a screening. For the training, women were screened using visual inspection with acetic acid, a method included in El Salvador’s guidelines at the time. Screen-positive women were assessed for cryotherapy treatment using the VAT criteria of phases I and II. In the subsequent 3 months, an experienced gynecologist conducted monitoring visits at the triage centers to ensure adequate implementation of clinical procedures. BHI personnel monitored program logistics. In phases one and two, four laboratory technicians had been trained in analysis of the HPV tests by staff from the test manufacturer; four technicians were added in phase III.

Recruitment of participants was conducted by CHPs, who live in the same communities where they work. CHPs are responsible for monitoring and recording the participation of 200-500 families in primary health care programs. CHPs used their records to identify and contact, through phone calls or home visits, age-eligible women who were under-screened, never screened, or due for screening. If a woman agreed, she was scheduled to attend her local health unit within 15 days to undergo HPV testing. Appointments were organized in groups of 10-20 women for the same day. Before testing, the health unit physician or nurse delivered a cervical cancer educational session to the women and explained follow-up procedures for women with positive results. Test samples were collected by the health unit staff and transported to four MOH laboratories for refrigerated storage at 8°C, as per the manufacturer’s instructions, and eventual analyses.

All women obtained an appointment to receive their results at the health unit in 30 days. Test samples can be run in 4-6 hours but must be processed in batches of 96 for the machine to run at full capacity. To maximize efficiency, tests were only run when batches were completed. The 30-day interval provided ample time to complete sample processing. During this period, unit nurses visited HPV-positive women at home to deliver their results. HPV-positive women were then scheduled to attend a triage center to undergo VAT and, if eligible, cryotherapy the same day. HPV-positive women who could not be reached were

![Patient flowchart of phase III of Cervical Cancer Prevention in El Salvador (CAPE).](image-url)
contacted at least two more times by a CHP and asked to make an appointment at a triage center to receive their results. HPV-negative women received their results at the 30-day appointment in their local health units and were recommended to be rescreened in 5 years. HPV-positive women who attended triage center appointments but were ineligible for ablation were referred to their regional hospital to undergo colposcopy and biopsy. Delivery of biopsy results and any subsequent procedures took place within the public health system but outside the context of CAPE.

Data collection instruments for screening and VAT were created by the MOH and BHI and are available online in El Salvador’s cervical cancer control guidelines. Colposcopy and biopsy information was recorded on standard MOH forms at hospitals. In phase I, BHI created and managed the only CAPE database while collaborating with the MOH to develop an online database that eventually became part of the El Salvador National Epidemiologic Surveillance System. In phases II and III, the CAPE online database was completed and management was transferred to the MOH. BHI received copies of data collection instruments and

| Characteristic                                      | Phase I (n = 1,000) | Phase II (n = 4,087) | Phase III (n = 17,965) | P* |
|-----------------------------------------------------|---------------------|----------------------|------------------------|----|
| Age, years                                          |                     |                      |                        |    |
| Mean (SD)                                           | 38.3 (5.8)          | 38.3 (5.6)           | 41.4 (8.2)             | < .001 |
| Median (min, max)                                   | 38 (27, 49)         | 38 (29, 54)          | 40 (20, 68)            |    |
| Highest level of formal education attained           |                     |                      |                        |    |
| None                                                | 118 11.8            | 650 15.9             | —                      | < .001 |
| Elementary                                          | 565 56.5            | 1,895 46.3           | —                      |    |
| Middle school                                       | 171 17.1            | 874 21.4             | —                      |    |
| High school                                         | 142 14.2            | 0 0                  | —                      |    |
| Missing                                             | 4 0.4               | 668 16.3             | —                      |    |
| No. of children                                     |                     |                      |                        |    |
| 0-2                                                 | 315 31.5            | 428 10.5             | —                      | < .001 |
| 3-4                                                 | 436 43.6            | 2,160 52.9           | —                      |    |
| ≥ 4                                                 | 243 24.3            | 1,457 35.7           | —                      |    |
| Missing                                             | 6 0.6               | 42 1                 | —                      |    |
| Age at first sexual intercourse, years              |                     |                      |                        |    |
| < 16                                                | 172 18.2            | 1,065 26.1           | —                      | < .001 |
| 16-19                                               | 515 51.5            | 1,879 46.0           | —                      |    |
| ≥ 20                                                | 303 30.3            | 1,086 26.6           | —                      |    |
| Missing                                             | 10 0                | 54 1.3               | —                      |    |
| No. of lifetime sexual partners                     |                     |                      |                        |    |
| 0-1                                                 | 529 52.9            | 1,856 45.4           | —                      | < .001 |
| 2                                                   | 277 27.7            | 1,296 31.7           | —                      |    |
| ≥ 3                                                 | 194 19.4            | 935 22.9             | —                      |    |
| Missing                                             | 0 0                 | 0 0                  | —                      |    |
| Last screen for cervical cancer                     |                     |                      |                        |    |
| Never                                               | 0 0                 | 511 12.5             | 1,382 7.7              | < .001 |
| ≥ 3 years ago                                       | 410 39.4            | 1,175 28.7           | 9,158 50               |    |
| ≤ 3 years ago                                       | 551 52.0            | 2,293 56.1           | 7,425 41.3             |    |
| Missing                                             | 79 7.6              | 108 2.64             | 0 0                   |    |
| Residence                                           |                     |                      |                        |    |
| Rural                                               | 896 89.6            | 3,469 84.9           | 13,797 76.8            | < .001 |
| Urban                                               | 104 10.4            | 618 15.1             | 4,168 23.2             |    |

Abbreviations: CAPE, Cervical Cancer Prevention in El Salvador; max, maximum; min, minimum; SD, standard deviation.

*Pearson’s χ² test for independence or two-tailed t test as appropriate.
maintained an independent database that was used for all analyses presented here.

For comparisons across phases, we used Wilcoxon-type trend tests for HPV positivity rates, Pearson’s $\chi^2$ and $t$ tests for sociodemographic variables and program indicators, and Kruskal-Wallis test for median number of days between procedures. The significance level was set at .05 for all tests. All statistical analyses were conducted using Stata 14.1 (StataCorp, College Station TX).

**Patients and Public Involvement Statement**

Patients and the public were not involved in the design, conduct, reporting, or dissemination of this project.

**RESULTS**

Results from CAPE phases I and II have been published previously.\textsuperscript{19,20} In phase III, 17,965 women were screened using careHPV (there are no data on women who were invited to participate but refused). The mean age for these participants was 41.4 years (standard deviation, 8.2 years) and the majority lived in rural areas (76.8%) versus urban areas (23.2%). Other demographic data collected in earlier phases were not collected during phase III. Available variables and differences found in the S&T cohorts across the three CAPE phases are listed in Table 1. In phase III, there was no effect of age, time since last screen, or area of residence on any of the loss to follow-up measures described below.

HPV positivity rates were 11.9% (119 of 1,000) in phase I, 11.4% (465 of 4,087) in phase II, and 12.3% (2,214 of 17,965) in phase III; these changes were not statistically significant (Wilcoxon-type trend test, $P = .173$).\textsuperscript{25} Age-adjusted HPV positivity rates also show little difference across the three phases (Table 2).

HPV-positive women were considered lost to follow-up (LTFU) if they did not complete indicated management (VAT and immediate cryotherapy or colposcopy, biopsy, and subsequent procedures) within 6 months. In phase III, 72.8% (1,612 of 2,214) of HPV-positive women completed VAT and cryotherapy within 6 months of screening (adherent), 4.6% (102 of 2,214) were classified as LTFU but returned and received VAT and cryotherapy after 6 months, 11.2% (248 of 2,214) were referred to colposcopy after VAT, and records for the remaining 11.4% (252 of 2,214) were missing.

Among women referred to colposcopy, 38.7% (96 of 248) attended the initial colposcopy appointment within 6 months, but treatment records were only available for 73 of these women. Of these, 19.0% (47 of 248) completed indicated treatment within 6 months (adherent), 6.5% (162 of 2,214) were classified as LTFU but returned and received VAT and cryotherapy after 6 months, and 4.0% (10 of 248) received treatment but had no treatment date. We were unable to confirm if the remaining 70.5% (175 of 248) were LTFU or returned for treatment but their records were missing. Thus, in phase III, a total of 75% (1,659 of 2,214) of women completed their indicated procedures within 6 months of screening, 5.3% (118 of 2,214) after 6 months, and the remaining 19.7% (437 of 2,214) were either LTFU or had missing data. However, when combining missing data with women

| Age Range (years) | El Salvador Female Population, 2007 Census | Phase One | Phase Two | Phase Three |
|------------------|------------------------------------------|-----------|-----------|------------|
| 30-34            | 223,849                                  | 0.13 (330) | 0.11 (1,247) | 0.15 (4,476) |
| 35-39            | 196,633                                  | 0.12 (237) | 0.11 (1,172) | 0.13 (4,086) |
| 40-44            | 171,413                                  | 0.13 (254) | 0.11 (952)  | 0.11 (3,273) |
| 45-49            | 142,165                                  | 0.08 (178) | 0.12 (715)  | 0.10 (2,577) |
| 50-54            | 120,459                                  | —         | —         | 0.09 (2,003) |
| 55-59            | 101,357                                  | —         | —         | 0.13 (1,533) |
| Total            | 955,876                                  | 0.12      | 0.11      | 0.12 |

**Abbreviations:** CAPE, Cervical Cancer Prevention in El Salvador; HPV, human papillomavirus.

\textsuperscript{a}Based on 999 observations: one patient excluded based on age lower than age range.

\textsuperscript{b}Based on 4,086 observations: one patient excluded based on age greater than age range.

\textsuperscript{c}Based on 17,948 observations: 11 patients excluded based on age lower than age range.

\textsuperscript{d}Exact confidence interval.
who completed treatment after 6 months, did not return for their HPV test results, and did not attend indicated procedures after referral. LTFU was 25.1% (555 of 2,214), which was significantly greater than phases I (6.7%) and II (7.7%; \( P > .001 \); Table 3).

In phase III, reasons women were referred to colposcopy after VAT were: lesion suspicious for cancer (9 of 248, 3.63%), pregnancy (2 of 248, 0.81%), and unsatisfactory VAT (215 of 248, 86.69%). Data are missing for the remaining women (22 of 248, 8.87%). Among referred cases, biopsy results and treatment records were available for 84 of 248 (34.27%) and 73 of 248 (29.4%) women, respectively. Reasons for referral to colposcopy, biopsy results, and treatment types across phases are listed in Table 4.

Delivery of HPV test results to all participating women was planned for 30 days after screening. As the project scaled up, the median day interval increased from 14 days (range, 1-379 days) in phase I to 41 days (range, 1-379 days) in phase I to 41 days (range, 1-379 days) in phase II (18 days; range, 0-319 days; \( P < .001 \)). The median number of days between colposcopy and treatment was also shorter in phase three than in phase II (14 days; range, 1-379 days; \( P < .001 \)). The median number of days between colposcopy and treatment was also shorter in phase three than in phase II (18 days; range, 0-319 v 42 days; range, 12-163 days; \( P < .001 \); data for phase I were not available; Table 5).

**TABLE 3.** HPV Positivity and LTFU, All CAPE Phases

| HPV Positivity and LTFU | Phase I | Phase II (n = 4,087) | Phase III (n = 17,965) | \( P^a \) |
|-------------------------|---------|---------------------|------------------------|--------|
| HPV+ women (out of all women in S&T) | 119 | 11.9 | 465 | 11.37 | 2,214 | 12.32 | .173 |
| LTFU total (out of all HPV+ women in S&T) | 0 | 6.72 | 54 | 7.74 | 555 | 25.06 | < .001 |
| Women referred to colposcopy (out of all HPV+ women in S&T) | 8 | 6.72 | 57 | 12.25 | 248 | 11.2 | .23 |
| LTFU referred women (out of HPV+ women in S&T who underwent VAT and were referred to colposcopy) | 0 | 100.0 | 43 | 61.4 | 201 | 81.04 | < .001 |

NOTE. Women were considered LTFU if they did not complete all indicated procedures within 6 months. Women referred to colposcopy because of pregnancy were considered as having completed indicated procedures and not LTFU.

Abbreviations: CAPE, Cervical Cancer Prevention in El Salvador; HPV, human papillomavirus; LTFU, lost to follow-up; S&T, screen-and-treat; VAT, visual assessment for treatment.

\(^a\)\( \chi^2 \) test for independence.

\(^b\)Includes only HPV-positive women who underwent VAT, were deemed ineligible for cryotherapy, were referred to colposcopy, but did not attend their colposcopy appointment and/or complete other follow-up procedures within 6 months. In a previously published article,19 one woman was reported as LTFU in phase one. Patient records were corrected since then, and numbers reported here reflect this update.

DISCUSSION

CAPE reached 28,050 underserved women in El Salvador and is the largest public-sector implementation program to date of an S&T protocol with a lower-cost HPV test.

As CAPE scaled up, there were increases in loss to follow-up rates. A study with nonattenders of conventional screening programs in the Paracentral region found that barriers to screening included embarrassment at being examined by a male doctor, misinformation about screening, and long wait times.26 High rates of migration may also play a role. Addressing such obstacles will be important to increase the future cost-effectiveness of the program.

An important limitation was inadequate data collection for women referred to colposcopy. In phase III, complete data for more than two-thirds of referred women were not available. Colposcopy and biopsy results came from the medical records of participating referral hospitals, and much of this information was not transferred to the electronic MOH database. Although it is impossible to determine if missing cases truly represent loss to follow-up, it is still the case that women referred to colposcopy face additional barriers to complete indicated procedures.

Another challenge was the long interval between screening and delivery of results to participants. This was partly due to the loss of two shipments of reagents for HPV test processing that occurred when cold-chain requirements were not followed correctly. Although this was eventually resolved, 562 samples were frozen at \(-20^\circ\text{C}\) for approximately 6 months until analyses could resume. However, there were no differences in HPV positivity between these
and the rest of the samples (12.39% vs. 12.32%, respectively; \( P = .962 \)). Overall, HPV-positive women were prioritized and received their results earlier than those who tested HPV negative. The limited number of colposcopists also contributed to long wait times between appointments for referred women. Although mean number of days between procedures decreased with scale-up, high rates of missing data make it difficult to interpret this change.

Table 6 provides a summary of obstacles that emerged during the implementation of the program.

Despite these setbacks, CAPE demonstrated the potential of public-private sector collaborations in cervical cancer prevention efforts. The initial impetus for the project came from the possibility of obtaining the careHPV tests via an industry program. As a nonprofit organization and a government agency, respectively, BHI and the MOH had different strengths and capabilities. With approval from the MOH, BHI designed phase I as a pilot study, hired a physician (K.A.) to act as project coordinator, and supervised trainings for health care providers. The MOH provided the necessary personnel and infrastructure and, as CAPE expanded, took ownership of the program, while BHI served as technical advisor.

Another key element in the success of CAPE was the commitment of the national government and other stakeholders, including academic institutions, professional medical associations in El Salvador, the National Institutes of Health, and the Pan-American Health Organization. BHI and MOH representatives organized meetings and presentations with experts and local authorities and an early field visit to Nicaragua to observe a project using HPV testing. CAPE outcomes were presented at the end of each phase to government officials, which increased support for the project.

**Table 4.** Referral to Colposcopy, Biopsy Results, and Treatment, Only Referred Women in All CAPE Phases

| Referral, Results, or Treatment | Phase I | Phase II | Phase III |
|--------------------------------|---------|----------|-----------|
| HPV+ women referred to colposcopy | 9 | 57 | 248 |
| **Reasons for referral** | | | |
| Lesion too extensive | 4 | 12 | 0 |
| Lesion extended into canal | 1 | 5 | 0 |
| Pregnancy | 1 | 1 | 0 |
| Inadequate/unsatisfactory VAT | 2 | 0 | 215 |
| Suspicious for cancer | 0 | 0 | 9 |
| Other | 1 | 30 | 0 |
| Missing | 0 | 9 | 22 |
| **Local pathology results** | | | |
| Negative | 0 | 1 | 4 |
| CIN2 | 8 | 18 | 74 |
| Unsatisfactory | 0 | 3 | 4 |
| Pregnant | 0 | 1 | 0 |
| Missing | 0 | 33 | 164 |
| **Treatment** | | | |
| Cryotherapy | 8 | 19 | 69 |
| LEEP | 0 | 1 | 1 |
| Cold knife cone | 0 | 0 | 1 |
| Hysterectomy | 0 | 1 | 2 |
| Missing | 0 | 39 | 175 |

**NOTE.** Includes all pathology results and treatments performed, before and after 6 months of screening date.

**Abbreviations:** CAPE, Cervical Cancer Prevention in El Salvador; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LEEP, loop electrosurgical excision procedure; VAT, visual assessment for treatment.

\( ^a \)No pregnancies were reported at later visits.

\( ^b \)Local pathology results in phase II differed from the diagnosis of an expert pathologist, but they were retained here for comparability because only local pathology was available in phase III.

\( ^c \)Almost half (44%) of women with unsatisfactory VAT were ≥ 50 years of age.
| Time Between:                          | Phase I                                    | Phase II                                   | Phase III                                  |
|---------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                       | Mean, Median (min, max)                    | Mean, Median (min, max)                    | Mean, Median (min, max)                    |
|                                       | 95% CI IQR                                 | 95% CI IQR                                 | 95% CI IQR                                 |
| Last screen/HPV screen                | 1,400, 931 (6, 9,290) 1,319 to 1,481        | 1,167,924 (0, 8,786) 1,138 to 1,196        | 1,419, 1,128 (0, 14,408) 1,403 to 1,435 |
|                                       | 727-1,598                                  | 744-1,277                                  | 853-1,546                                  |
|                                       |                                            |                                            |                                            |
| HPV screen/return of results           | 23, 14 (2, 379) 21 to 24                    | 46, 41 (1, 391) 45 to 47                   | 99, 74 (1, 761) 98 to 101                   |
| (all)                                 |                                            |                                            |                                            |
| HPV screen/return of results           | 23, 14 (6, 205) 18 to 27                    | 46, 41 (5, 382) 42 to 49                   | 80, 65 (1, 713) 77 to 82                    |
| (HPV+)                                |                                            |                                            |                                            |
| HPV screen/return of results           | 23, 14 (2, 379) 21 to 25                    | 46, 41 (1,391) 45 to 47                    | 102, 76 (1, 761) 101 to 104                  |
| (HPV−)                                |                                            |                                            |                                            |
| HPV screen/colposcopy                 | 140, 137 (27, 274) 31 to 248                | 93, 88 (44, 224) 80 to 106                  | 132, 98 (37, 680) 110 to 154                 |
|                                       |                                            |                                            |                                            |
| Colposcopy/treatment                  | —                                          | —                                          | —                                          |

NOTE. All values rounded for clarity

Abbreviations: CAPE, Cervical Cancer Prevention in El Salvador; HPV, human papillomavirus; IQR, interquartile range; max, maximum; min, minimum.

*Kruskal-Wallis test.

Three women excluded because of negative values, 1 for values > 14,600 days (40 years).

Twenty-six women excluded because of negative values, 1,784 for values > 14,600 days (40 years).
The lean model of CAPE, based on the efficient use of the MOH’s existing resources, helped transform it into a sustainable initiative. Findings from CAPE were instrumental in changing El Salvador cervical cancer guidelines to recommend HPV testing and S&T.24 Although data collection and management need improvement, the MOH now has a digital surveillance system for cervical cancer. Crucially, the MOH has now procured 160,000 lower-cost HPV tests to implement a national expansion of CAPE over the next 2 years. CAPE demonstrated that linking lower-cost HPV screening to a protocol that favors follow-up treatment over colposcopy and cytology can achieve high coverage levels in a low-resource setting. Similar ongoing projects in other Central American countries will provide additional data to inform the optimal deployment of this paradigm.

**AFFILIATIONS**

1Basic Health International, San Salvador, El Salvador and New York, NY
2Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
3Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
4Division of Cancer Prevention and Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH/DHHS, Rockville, MD
5Keck School of Medicine, University of Southern California, Los Angeles, CA
6Unidad de Cáncer, Ministerio de Salud República de El Salvador, San Salvador, El Salvador
7Ob/Gyn & Women’s Health Institute, Cleveland Clinic, Cleveland, OH

**CORRESPONDING AUTHOR**

Montserrat Soler, PhD, Ob/Gyn & Women’s Health Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195; Twitter: @BasicHealth; e-mail: solerm@ccf.org.

**TABLE 6. Summary of Barriers and Solutions Encountered During the Implementation of the CAPE Program**

| Barriers                                                                 | Solutions                                                                 |
|------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Reluctance by local stakeholders to change cytology-based screening program to HPV testing | Stakeholder meetings with professional associations, government officials, and international experts<br>Phased-in approach to demonstrate program success |
| Few gynecologists and specialized personnel and limited number of triage and referral centers | Data from a pilot project and a regional scale-up were used to change national guidelines to design a program based on the local system’s existing personnel and infrastructure<br>Changes included the introduction of screening and treatment methods that require relatively minimal technology and expertise, extensive training sessions before the beginning of the program at all personnel levels (health care providers, laboratory staff, data entry specialists), and continuous monitoring and on-site visits at health clinics by experienced gynecologists |
| Loss to follow-up increased as program expanded                         | Multiple attempts to contact participants by CHPs and health unit nurses and doctors<br>Conduct at-home visits to encourage program adherence when possible<br>Situate triage centers in central or easily accessible areas<br>Improve information system to facilitate patient follow-up and maintain accurate and updated records (ongoing) |
| Long intervals between program steps                                    | Batch HPV tests and schedule groups of women to receive results at predetermined days to increase efficiency<br>Provide eligible HPV-positive women with appointments to colposcopy clinics at the same time as the delivery of results/triage visit<br>Prioritize result delivery to HPV-positive women<br>A more effective information system would optimize program management and reduce time intervals between steps |
| Limited number of colposcopists to conduct referral examinations         | Establish a line of communication between triage centers and colposcopy clinics to schedule and prioritize program participants |
| Logistic issues (ie, loss of reagents because of incorrect shipping information) | Use specialized courier and transportation services<br>Assign dedicated personnel to supervise customs requirements, shipping, storage, and transportation of supplies<br>Use local distributors when possible |
| Incomplete or missing program data                                       | Work closely with local authorities to create a database and data collection system (including sufficient trained personnel to input and manage data)<br>Periodic monitoring of database to ensure adequate data entry<br>Improve communication between local actors at different levels to ensure appropriate data collection, management, and sharing |

Abbreviations: CAPE, Cervical Cancer Prevention in El Salvador; CHP, community health promoter; HPV, human papillomavirus.
Implementation of Cervical Screen-and-Treat Program

Presented at Eurogin, Salzburg, Austria, June 15-18, 2016; the International Papillomavirus Conference (IPVC), Cape Town, South Africa, February 28-March 4, 2017; and American Society for Colposcopy and Cervical Pathology (ASCCP), Las Vegas, Nevada, April 18-21, 2018.

SUPPORT
The Cervical Cancer Prevention in El Salvador (CAPE) project was funded by PATH (1867-00640013-SUB) and the Einhorn Family Charitable Trust; HPV tests were donated by QiagenCares.

AUTHOR CONTRIBUTIONS
Conception and design: Karla Alfaro, Mauricio Maza, Juan C. Felix, Julia C. Gage, Philip E. Castle, Todd A. Alonzo, Andrea Chacón, Enrique González, Montserrat Soler, Rachel Masch, Miriam Cremer
Administrative support: Andrea Chacón
 Provision of study material or patients: Andrea Chacón, Enrique González
 Collection and assembly of data: Karla Alfaro, Mauricio Maza, Juan C. Felix, Philip E. Castle, Montserrat Soler, Gabriel Conzuelo-Rodriguez, Rachel Masch
 Data analysis and interpretation: Karla Alfaro, Mauricio Maza, Juan C. Felix, Julia C. Gage, Philip E. Castle, Todd A. Alonzo, Montserrat Soler, Gabriel Conzuelo-Rodriguez, Miriam Cremer
 Manuscript writing: All authors
 Final approval of manuscript: All authors
 Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rc or ascopubs.org/go/site/misc/authors.html.

Juan C. Felix
Expert Testimony: Ethicon

Rachel Masch
Employment: Basic Health International
Honoraria: Health Logic
Consulting or Advisory: Bayer
Speakers’ Bureau: Merck
Travel, Accommodations, Expenses: Merck
Research Funding: Basic Health International

Phillip E. Castle
Research Funding: Roche, Becton Dickinson, Arbor Vita Corporation, Cepheid

Miriam Cremer
Honoraria: Merck
Consulting or Advisory Role: Merck
Speakers’ Bureau: Merck
Travel, Accommodations, Expenses: Merck

Other Relationship: Basic Health International

No other potential conflicts of interest were reported.

REFERENCES
1. Koliopoulos G, Nyaga VN, Santesso N, et al: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 8: CD008587, 2017
2. Lew JB, Simms KT, Smith MA, et al: Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: Effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health 2:e96-e107, 2017
3. Goldie SJ, Gaffken L, Goldhaber-Fiebert JD, et al: Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353:2158-2168, 2005
4. Goldie SJ, Kuhn L, Denny L, et al: Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness. JAMA 286:3107-3115, 2001
5. World Health Organization (WHO): Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/index.html
6. Denny L, Kuhn L, De Souza M, et al: Screen-and-treat approaches for cervical cancer prevention in low-resource settings: A randomized controlled trial. JAMA 294:2173-2181, 2005
7. Kuhn L, Wang C, Tsai WY, et al: Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 24:2553-2561, 2010
8. Viviano M, Kenfack B, Catarino R, et al: Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa. BMC Womens Health 17:2, 2017
9. Tran PL, Kenfack B, Tincho Foguem E, et al: Efficacy of thermocoagulation in treating cervical precancerous lesions in a low-resource setting. Int J Womens Health 9:879-886, 2017
10. WHO: Prequalification of In Vitro Diagnostics: Public Report. Product: careHPV Test. https://www.who.int/diagnostics_laboratory/evaluations/pq-list/180713_pqpr_pqdx_0085_028_00_carehpv_with_labeling.pdf
11. Qiao YL, Sellors JW, Eder PS, et al: A new HPV-DNA test for cervical-cancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China. Lancet Oncol 9:929-936, 2008
12. Zhao FH, Jeronimo J, Qiao YL, et al: An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) 6:938-948, 2013
13. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, et al: Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA study. Revista Puebla Mex 58:197-210, 2016
14. Arrossi S, Thouyaret L, Laudi R, et al: Implementation of HPV-testing for cervical cancer screening in programmatic contexts: The Jujuy demonstration project in Argentina. Int J Cancer 137:1709-1718, 2015
15. Arrossi S, Thouyaret L, Herrero R, et al: Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): A population-based cluster-randomised trial. Lancet Glob Health 3:e85-e94, 2015
16. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E399-E386, 2015
17. Murillo R, Almonte M, Pereira A, et al: Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 26:L37-L48, 2008 (suppl 11)
18. Maza M, Matesanz S, Alfaro K, et al: Adherence to recommended follow-up care after high-grade cytology in El Salvador. Int J Healthc 2:31, 2016
19. Cremer ML, Maza M, Alfaro KM, et al: Introducing a high-risk HPV DNA test into a public sector screening program in El Salvador. J Low Genit Tract Dis 20:145-150, 2016
20. Cremer M, Maza M, Alfaro K, et al: Scale-up of an human papillomavirus testing implementation program in El Salvador. J Low Genit Tract Dis 21:26-32, 2017
21. Campos NG, Maza M, Alfaro K, et al: The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer 137:893-902, 2015
22. Campos NG, Maza M, Alfaro K, et al: The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. Int J Gynaecol Obstet 145:40-46, 2019
23. Ministerio de Salud de El Salvador: Informe de la consulta nacional sobre el documento de propuesta: Estrategia para la cobertura universal de salud. El Salvador, Julio 2014.
24. Ministerio de Salud de El Salvador, Viceministerio de Politicas de Salud: Lineamientos técnicos para la prevención y control del cáncer cervical uterino y de mama. 1° Edición. San Salvador, El Salvador: Diseñarte SA de CV; 2015. http://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientos_prevencion_cancer_cervico_uterino_y_de_mama_v3.pdf
25. Cuzick JA: A Wilcoxon-type test for trend. Stat Med 4:543-547, 1985
26. Maza M, Melendez M, Masch R, et al: Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. Prev Med 114:149-155, 2018

© 2020 by American Society of Clinical Oncology